Skip to Content
Søk Menu

Venetoclax in combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Relatert innhold

Fredrik Hellem Schjesvold

Melflufen is Safe and Effective in Patients with Alkylator-Refractory Disease

/ Fredrik Schjesvold
Myelomatose Play the Video 4:41
Pieter Sonneveld

A Potential New Standard of Care for Transplant-Eligible Patients with Multiple Myeloma

/ Pieter Sonneveld
ASH23Myelomatose Play the Video 05:04
Evangelos Terpos

Daratumumab Combination Shows Positive Responses in Pretreated R/R Multiple Myeloma.

/ Evangelos Terpos
EHA23Myelomatose Play the Video 6:39

Belamaf and Dexamethasone – Safe, Effective Multiple Myeloma Treatment

/ Evangelos Terpos / Jan Andreasen
EHA23Myelomatose
Fredrik Schjesvold

EHA23 Insights into the Changing Landscape of Myeloma Treatments

/ Fredrik Schjesvold
EHA23Myelomatose Play the Video 4:39
Sagar Lonial

Exciting News for CAR T Cell Therapy to Heavily Treated Patients with Multiple Myeloma

/ Sagar Lonial
ASCO23CAR-TEHA23Myelomatose Play the Video 02:20
Rakesh Popat

Integrating BCMA-Based Combination Regimens in Early R/R Multiple Myeloma

/ Rakesh Popat
EHA23Myelomatose Play the Video 03:23

High Expression of the Inhibitory Checkpoint Receptor TIGIT by CD8+ T-cells in Multiple Myeloma

/ Katrine Fladeland Iversen
MyelomatoseT-celler
Paul Richardson

New combination shows promising efficacy in patients with triple-class refractory R/R multiple myeloma

/ Paul G. Richardson
ASH22Myelomatose Play the Video 2:58
Back to top